Tyra Biosciences grants options to director

Tyra Biosciences director Stephen Michael Rothenberg received a new stock option grant covering 13,160 shares of common stock.

Rhea-AI Filing Summary

Tyra Biosciences director Stephen Michael Rothenberg received a new stock option grant covering 13,160 shares of common stock. The options have an exercise price of $32.68 per share and expire on May 27, 2036. The grant was made under the company’s Non-Employee Director Compensation Program.

Vesting is structured so that 1/12 of the option vests monthly after the May 28, 2026 grant date. If the next annual stockholder meeting occurs before the first anniversary of grant, any remaining unvested portion vests on that meeting date, subject to continued service.

Insider Trade Summary

Grant/Award: 13,160 shares

Grant/Award 1 txn

Insider Rothenberg Stephen Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,160	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 13,160 contracts (Direct)

Footnotes (1)

1. F1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Option grant size: 13,160 shares Exercise price: $32.68 per share Expiration date: May 27, 2036 +1 more

4 metrics

Option grant size 13,160 shares Stock option award to director on May 28, 2026

Exercise price $32.68 per share Strike price for director stock options

Expiration date May 27, 2036 Option term for director grant

Post-grant derivative holdings 13,160 options Total stock options held following this transaction

Key Terms

Non-Employee Director Compensation Program, Stock Option (Right to Buy), vesting, Common Stock

4 terms

Non-Employee Director Compensation Program financial

"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vesting financial

"1/12th of the total number of shares of common stock subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tyra Biosciences (TYRA) report for Stephen Michael Rothenberg?

Tyra Biosciences reported a grant of stock options to director Stephen Michael Rothenberg for 13,160 shares of common stock. This award is part of the company’s Non-Employee Director Compensation Program and reflects routine equity-based director compensation rather than an open-market trade.

What are the key terms of Stephen Rothenberg’s Tyra Biosciences (TYRA) stock options?

Stephen Rothenberg’s options cover 13,160 shares of Tyra Biosciences common stock at an exercise price of $32.68 per share. The options expire on May 27, 2036 and were granted with no cash paid upfront, reflecting a standard equity compensation award for a non-employee director.

How do Stephen Rothenberg’s Tyra Biosciences (TYRA) options vest over time?

The options vest in 12 equal monthly installments starting after the May 28, 2026 grant date, with 1/12 of the shares vesting each month. If the next annual stockholder meeting occurs before the first anniversary, any remaining unvested options vest at that meeting, assuming continued service.

Did Stephen Rothenberg buy or sell Tyra Biosciences (TYRA) shares in this Form 4?

This Form 4 reports an acquisition of stock options as compensation, not a market purchase or sale of shares. Rothenberg was granted 13,160 options with a $32.68 exercise price, so the transaction represents a grant/award rather than immediate buying or selling in the open market.

What is the expiration date of Stephen Rothenberg’s Tyra Biosciences (TYRA) stock options?

Stephen Rothenberg’s stock options expire on May 27, 2036, giving him a long-term window to exercise them once vested. The options cover 13,160 underlying common shares at a fixed exercise price of $32.68, aligning director incentives with the company’s longer-term share performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rothenberg Stephen Michael

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.68	05/28/2026		A		13,160		(1)	05/27/2036	Common Stock	13,160	$0	13,160	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Ali D. Fawaz, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)